滑膜肉瘤：临床病理变量对英国人群总生存率的影响

IF 2.3 4区医学 Q3 ONCOLOGY

Surgical Oncology-Oxford Pub Date : 2025-03-05 DOI:10.1016/j.suronc.2025.102204

Bill Robertson-Smith , Jackie Campbell , Karen Anthony , Thomas A. McCulloch , Robert U. Ashford

{"title":"滑膜肉瘤：临床病理变量对英国人群总生存率的影响","authors":"Bill Robertson-Smith , Jackie Campbell , Karen Anthony , Thomas A. McCulloch , Robert U. Ashford","doi":"10.1016/j.suronc.2025.102204","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Synovial sarcoma accounts for 5%–10 % of malignant soft-tissue tumours. Curative treatment includes surgery, with radiotherapy and/or chemotherapy. With no specific treatment regimen for synovial sarcoma, the primary aim of this research was to describe the characteristics of a regional synovial sarcoma population in the UK, and to investigate clinicopathological variables associated with overall survival.</div></div><div><h3>Methods</h3><div>Ninety-four patients with synovial sarcoma from the East Midlands Sarcoma Service database were pseudo anonymised and clinicopathological variables extracted. Kaplan-Meier and Cox regression statistical analyses were used to identify variables affecting overall survival.</div></div><div><h3>Results</h3><div>Mean age at diagnosis was 42 years (range 8–83 years). Over half (n = 50, 53 %) of patients had a tumour in the lower limb. Thirty-seven (39.6 %) had a tumour size of <5 cm. Sixteen (17 %) patients had local recurrence, and under half (n = 40, 43.5 %) developed metastatic disease. Most patients (n = 63, 63 %) were initially treated with surgery. The majority (n = 58, 61.7 %) had a monophasic subtype, and the overall survival of the whole cohort was 83 months (95 % CI 39.1–127.8). Increasing tumour size and distant recurrence (metastasis) had a significantly negative impact on median overall survival (<em>p</em> = 0.0001). Patients who underwent surgery and radiotherapy had a significantly better median overall survival (<em>p</em> = 0.02). Multivariable analysis identified adjuvant radiotherapy (<em>p</em> = 0.039), lower limb tumour (<em>p</em> = 0.033), and tumour size (<5 cm <em>p</em> = 0.006, 5–10 cm <em>p</em> = 0.0001, >10 cm <em>p</em> = 0.013) as significant survival predictors.</div></div><div><h3>Conclusion</h3><div>Adjuvant radiotherapy is a novel independent prognostic marker for synovial sarcoma.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"59 ","pages":"Article 102204"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synovial sarcoma: The influence of clinicopathological variables on overall survival in a UK population\",\"authors\":\"Bill Robertson-Smith , Jackie Campbell , Karen Anthony , Thomas A. McCulloch , Robert U. Ashford\",\"doi\":\"10.1016/j.suronc.2025.102204\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Synovial sarcoma accounts for 5%–10 % of malignant soft-tissue tumours. Curative treatment includes surgery, with radiotherapy and/or chemotherapy. With no specific treatment regimen for synovial sarcoma, the primary aim of this research was to describe the characteristics of a regional synovial sarcoma population in the UK, and to investigate clinicopathological variables associated with overall survival.</div></div><div><h3>Methods</h3><div>Ninety-four patients with synovial sarcoma from the East Midlands Sarcoma Service database were pseudo anonymised and clinicopathological variables extracted. Kaplan-Meier and Cox regression statistical analyses were used to identify variables affecting overall survival.</div></div><div><h3>Results</h3><div>Mean age at diagnosis was 42 years (range 8–83 years). Over half (n = 50, 53 %) of patients had a tumour in the lower limb. Thirty-seven (39.6 %) had a tumour size of <5 cm. Sixteen (17 %) patients had local recurrence, and under half (n = 40, 43.5 %) developed metastatic disease. Most patients (n = 63, 63 %) were initially treated with surgery. The majority (n = 58, 61.7 %) had a monophasic subtype, and the overall survival of the whole cohort was 83 months (95 % CI 39.1–127.8). Increasing tumour size and distant recurrence (metastasis) had a significantly negative impact on median overall survival (<em>p</em> = 0.0001). Patients who underwent surgery and radiotherapy had a significantly better median overall survival (<em>p</em> = 0.02). Multivariable analysis identified adjuvant radiotherapy (<em>p</em> = 0.039), lower limb tumour (<em>p</em> = 0.033), and tumour size (<5 cm <em>p</em> = 0.006, 5–10 cm <em>p</em> = 0.0001, >10 cm <em>p</em> = 0.013) as significant survival predictors.</div></div><div><h3>Conclusion</h3><div>Adjuvant radiotherapy is a novel independent prognostic marker for synovial sarcoma.</div></div>\",\"PeriodicalId\":51185,\"journal\":{\"name\":\"Surgical Oncology-Oxford\",\"volume\":\"59 \",\"pages\":\"Article 102204\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgical Oncology-Oxford\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0960740425000192\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960740425000192","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

滑膜肉瘤占软组织恶性肿瘤的5% - 10%。治愈性治疗包括手术、放射治疗和/或化疗。由于滑膜肉瘤没有特定的治疗方案，本研究的主要目的是描述英国区域滑膜肉瘤人群的特征，并调查与总生存率相关的临床病理变量。方法对来自East Midlands肉瘤服务数据库的94例滑膜肉瘤患者进行伪匿名，提取临床病理变量。Kaplan-Meier和Cox回归统计分析用于确定影响总生存率的变量。结果平均诊断年龄42岁（范围8 ~ 83岁）。超过一半（n = 50,53 %）的患者在下肢有肿瘤。37例（39.6%）肿瘤大小为5cm。16例（17%）患者出现局部复发，不到一半（n = 40, 43.5%）患者出现转移性疾病。大多数患者（n = 63,63 %）最初接受手术治疗。大多数患者（n = 58, 61.7%）为单相亚型，整个队列的总生存期为83个月（95% CI 39.1-127.8）。增大肿瘤大小和远处复发（转移）对中位总生存期有显著的负面影响（p = 0.0001）。接受手术和放疗的患者的中位总生存期明显更好（p = 0.02）。多变量分析发现辅助放疗（p = 0.039）、下肢肿瘤（p = 0.033）和肿瘤大小（<5 cm p = 0.006, 5 - 10 cm p = 0.0001, >10 cm p = 0.013）是显著的生存预测因素。结论辅助放疗是滑膜肉瘤新的独立预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Synovial sarcoma: The influence of clinicopathological variables on overall survival in a UK population

Introduction

Synovial sarcoma accounts for 5%–10 % of malignant soft-tissue tumours. Curative treatment includes surgery, with radiotherapy and/or chemotherapy. With no specific treatment regimen for synovial sarcoma, the primary aim of this research was to describe the characteristics of a regional synovial sarcoma population in the UK, and to investigate clinicopathological variables associated with overall survival.

Methods

Ninety-four patients with synovial sarcoma from the East Midlands Sarcoma Service database were pseudo anonymised and clinicopathological variables extracted. Kaplan-Meier and Cox regression statistical analyses were used to identify variables affecting overall survival.

Results

Mean age at diagnosis was 42 years (range 8–83 years). Over half (n = 50, 53 %) of patients had a tumour in the lower limb. Thirty-seven (39.6 %) had a tumour size of <5 cm. Sixteen (17 %) patients had local recurrence, and under half (n = 40, 43.5 %) developed metastatic disease. Most patients (n = 63, 63 %) were initially treated with surgery. The majority (n = 58, 61.7 %) had a monophasic subtype, and the overall survival of the whole cohort was 83 months (95 % CI 39.1–127.8). Increasing tumour size and distant recurrence (metastasis) had a significantly negative impact on median overall survival (p = 0.0001). Patients who underwent surgery and radiotherapy had a significantly better median overall survival (p = 0.02). Multivariable analysis identified adjuvant radiotherapy (p = 0.039), lower limb tumour (p = 0.033), and tumour size (<5 cm p = 0.006, 5–10 cm p = 0.0001, >10 cm p = 0.013) as significant survival predictors.

Conclusion

Adjuvant radiotherapy is a novel independent prognostic marker for synovial sarcoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Surgical Oncology-Oxford 医学-外科

CiteScore

4.50

自引率

0.00%

发文量

169

审稿时长

38 days

期刊介绍： Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.